comparemela.com

Latest Breaking News On - Octagon capital - Page 7 : comparemela.com

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022

– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through. | May 9, 2022

United statesUnited kingdomTheresa boniRob rossScott youngExchange commissionAmerican association for cancer researchAmerican society of clinicalSurface oncology incGlobenewswire incAnnual meetingSubsequent corporateOctagon capitalCancer researchTrial progressInvestigational new drug

Vedere Bio II to Present Two Abstracts at the ASGCT 2022 Annual Meeting

CAMBRIDGE, Mass., May 2, 2022 /PRNewswire/ Vedere Bio II, Inc., a company developing transformative, next-generation therapies for vision resto.

United kingdomUnited statesPrnewswire vedere bio ii incMission biocapitalMeeting of the american society geneDevelopment or manufacturingVedere bio ii incRd fundAnnual meetingAmerican societyCell therapyIntravitreal deliveryCharacterizing novelNon human primatesSuspension cell lineCits platform

Vedere Bio II Appoints Accomplished Clinician and Researcher Anna-Maria Demetriades as Chief Medical Officer

CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ Vedere Bio II, Inc., a company developing transformative, next-generation therapies for vision re.

United statesUnited kingdomAnna maria demetriadesCyrus mozayeniPrnewswire vedere bio ii incGlaucoma service at weill cornell medicineBascom palmer eye instituteWilmer eye instituteVedere bio ii incUniversity of oxfordPhysiological sciencesMission biocapitalUniversity of miami miller school medicineAccess consortiumRoche groupRd fund

Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy

AnHeart Therapeutics is developing a pipeline of precision oncology therapeutics. Chief Business Officer and Co-founder Lihua Zheng provided an overview of company's strategy in response to emailed questions.

New yorkUnited statesColumbia universityInnovent biologicsLihua zhengBing yanJunyuan jerry wangNature communicationsColumbia university medical centerBaylor college of medicineChinese society of clinical oncologyHeart therapeuticsBusiness officerCo founder lihua zhengNew york basedChief medical officer

China CDE Approved First Universal CAR-T IND !

/PRNewswire/ On March 17, 2022, China National Drug Administration Drug Review Center (CDE) approved first Universal Chemeric Antigen Receptor T (UCAR-T).

Immunotherapy excellence centerNational intellectual property management enterpriseChina national drug administration review centerUnicorn enterprisesInnovation talents program of jiangsu provinceNational scienceBioheng biotech co ltdHillhouse venture capitalDecheng capitalOctagon capitalJiangsu provinceNanjing high level entrepreneurial talent planNanjing expert studioNanjing bioheng biotech co

vimarsana © 2020. All Rights Reserved.